Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA…

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamabFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentIgA Nephropathy (IgAN) is a leading cause of chronic kidney disease with up to 40% of IgAN patients progressing...

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at…

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months 1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients' historic rapid decline 1 Fabhalta also showed a favorable safety profile with no new safety signals 1 Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney...

Pioneering Carbon-Neutral Standards: The 136th Canton Fair Sets a New Industry…

In the spring of 2014, Canton Fair took the lead in implementing a green development plan – in only two years, the 120th Canton Fair had realized a 100 percent green booth setup. This year, Canton Fair is placing an even greater emphasis on encouraging exhibitors to use professional, environmentally friendly materials in innovative designs to further enhance the aesthetics of exhibition booths. In the spring of 2014, Canton Fair took the lead in implementing a green development plan – in only...

The 136th Canton Fair Highlights Product Innovation to Support a Greener Economy

Green stainless-steel products champion eco-friendly life Green stainless-steel products champion eco-friendly life Notable exhibitors include Guangdong Master Group Co., Ltd., which has developed the world's first green stainless-steel cookware with independent intellectual property rights. The product is the first of its kind to obtain the Green Product Mark certificate from TÜV Rheinland. "We need to focus on developing green products for a sustainable future," said Ou Shuhui,...

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of…

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024Selected for late-breaking oral presentation at ASN kidney week, the world's premier nephrology meetingResults presented show a statistically significant and clinically meaningful improvement of the prospectively defined kidney function parameter eGFR 1by 3.4mL/min/year (p<0.0001) in the varoglutamstat arm compared to placebo Results in the...

BIOVAXYS PROVIDES PRIVATE PLACEMENT UPDATES

The Private Placement was originally announced on July 23, 2024 (up to 10,000,000 Units for up to $500,000), and upsized on each of July 26, 2024 (up to 20,000,000 Units for up to $1,000,000), and September 20, 2024 (up to 30,000,000 Units for up to $1,500,000). Tranches of the Private Placement closed on each of July 29, 2024, August 2, 2024, September 11, 2024, September 23, 2024, and October 4, 2024. The Private Placement was originally announced onJuly 23, 2024(up to 10,000,000 Units...

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.Vestal Point CapitalOn October 23, 2024, Nyxoah received a transparency notification from...

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase…

NeoMab mice utilize human V(D)J gene-encoded antibodies, exhibiting gene usage frequency and sequence diversity similar to humans, making them suitable for fully human antibody development. Their competent immune system is capable of efficiently performing antigen presentation, antibody production, and affinity maturation. The unique BALB/c genetic background and antigen presentation system enhance the ability to present antigens, with serum titers reaching 10^5 to 10^6 after 3-4 rounds of…

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Oslo, October 25, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial (NCT05075122) have been published online on the preprint platform medRxiv. As previously reported , topline data readout demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall...

Neuromorphic Computing Market worth $1,325.2 million by 2030 - Exclusive Report…

Browse in-depth TOC on "Neuromorphic Computing Market" 167 – Tables69 – Figures256 – Pages Browse in-depth TOC on "Neuromorphic Computing Market" 167 – Tables 69 – Figures 256 – Pages Neuromorphic Computing Market Report Scope: By Offering, software segment is projected to grow at a high CAGR of neuromorphic computing market during the forecast period. The software segment is expected to grow at a fast rate in the forecasted period. Neuromorphic software has its roots in...

Orexo initiates new study of OX640 in participants with allergic rhinitis

The study is a cross-over study in 30 participants with allergic rhinitis and involves four treatment periods. In one of the periods, a small dose of an allergen will be sprayed into the nose of the participants to trigger an allergic reaction before being treated with OX640. This will be compared with absorption of epinephrine from OX640 without the allergen, and a commercial intramuscular epinephrine product. The fourth period will be used to document dose proportionality of OX640. In addition…

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT.An audio webcast of the conference presentation will also be available to...

Endo Announces Peyronie's Disease Presentation at the SurgeWest Annual Meeting…

The Endo-supported research presentation is below: The Endo-supported research presentation is below: About the Post Hoc Phase 3 Data Analysis 1 A post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled Phase 3 trials was conducted to evaluate CCH treatment and improvement in penile curvature in participants presenting with/without penile pain at baseline and disease duration of 12–18 months or >18 months. CCH-treated participants were stratified by...

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Investors, analysts, and members of the media are invited to a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri following the American Society of Nephrology (ASN) and a Q&A session. Investors, analysts, and members of the media are invited to a conference call onTuesday, October 29th, at12:00 CET,11:00 GMT, and07:00 EDT. The call will include a...

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at…

Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in 2H in 2025VANCOUVER, British Columbia, Oct.25, 2024(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug...

Microencapsulation Market worth $24.07 billion by 2029 - Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438 Browse in-depth TOC on "Microencapsulation Market" 250 – Tables 80 – Figures 350 – Pages The Food & Beverage Ingredients is the having a significant share within the Core Material sector of the microencapsulation market. Increasing demand for functional and fortified food products...

Clock Change Chaos: 40% of Shift Workers Struggle with Sleep as Clocks Go Back

These challenges extend beyond the clock change, with 49% of shift workers experiencing winter energy dips due to shorter daylight. As a result, 40% rely on energy drinks to stay alert and 14% admit to consuming four or more per shift, raising concerns about energy crashes and sugar intake. These challenges extend beyond the clock change, with 49% of shift workers experiencing winter energy dips due to shorter daylight. As a result, 40% rely on energy drinks to stay alert and 14% admit to...

Meret Gaugler, PhD, joins Page Therapeutics as independent member of the Board…

"Meret will bring us invaluable strategic insights as we are moving from an early-stage discovery company to a structured biotech, preparing our drug candidate for clinical trials" commented Nicola Aceto, Professor of Molecular Oncology at ETH Zurich and Page's scientific founder. "Our innovative approach targeting the dissociation of circulating tumour cell clusters to inhibit their potential to form metastases needs a strict development process as well as long term vision and…

Bridge to Life and ULS Coimbra Announce Collaboration to Enhance Preservation of…

The initiative kicks off with the development and launch of a case study demonstrating the important organ transplantation research and procedures being conducted at ULS Coimbra. The initiative kicks off with the development and launch of a case study demonstrating the important organ transplantation research and procedures being conducted at ULS Coimbra. "Bridge to Life is excited to support the innovations and advancements in organ transplantation at ULS Coimbra and look forward to...

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated…

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performanceParis, October 25, 2024Q3 sales growth of 15.7% at CER and business EPS (1)of €2.86Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmedPharma launches up 67.1% to €727 million, led by ALTUVIIIO, Nexviazyme and RezurockVaccines sales up 25.5%, boosted by phasing of flu sales, and by...

BioSenic provides third quarter 2024 Business Update

/C O R R E C T I O N -- Seegene Inc./

Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment…

Gifts & Decorations Category at the 136th Canton Fair Reflects Sustainable…

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA…

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at…

Pioneering Carbon-Neutral Standards: The 136th Canton Fair Sets a New Industry…

The 136th Canton Fair Highlights Product Innovation to Support a Greener Economy

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of…

BIOVAXYS PROVIDES PRIVATE PLACEMENT UPDATES

Publication relating to transparency notifications

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase…

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Neuromorphic Computing Market worth $1,325.2 million by 2030 - Exclusive Report…

Orexo initiates new study of OX640 in participants with allergic rhinitis

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London…

Endo Announces Peyronie's Disease Presentation at the SurgeWest Annual Meeting…

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at…

Microencapsulation Market worth $24.07 billion by 2029 - Exclusive Report by…

Clock Change Chaos: 40% of Shift Workers Struggle with Sleep as Clocks Go Back

Meret Gaugler, PhD, joins Page Therapeutics as independent member of the Board…

Bridge to Life and ULS Coimbra Announce Collaboration to Enhance Preservation of…

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated…